Imatinib mesylate, a selective inhibitor of BCR-ABL, in chronic myeloid leukemia.
Carella
Angelo Michele
AM
D000255:Adenosine Triphosphate / Q000378:metabolism; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001549:Benzamides; D001665:Binding Sites / Q000187:drug effects; D018592:Cross-Over Studies; D003561:Cytarabine / Q000008:administration & dosage; D018572:Disease-Free Survival; D015195:Drug Design; D019008:Drug Resistance, Neoplasm; D015507:Drugs, Investigational; D005060:Europe; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000601:surgery; D015337:Multicenter Studies as Topic; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000502:physiology; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D014184:Transplantation, Homologous; D016896:Treatment Outcome; D018909:src Homology Domains / Q000187:drug effects
D000970:Antineoplastic Agents; D001549:Benzamides; D015507:Drugs, Investigational; D016898:Interferon-alpha; D009363:Neoplasm Proteins; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D003561:Cytarabine; D000068877:Imatinib Mesylate; D000255:Adenosine Triphosphate; D016044:Fusion Proteins, bcr-abl